INTRODUCTION {#sec1-1}
============

Proteomics is the study of protein expression in a definite tissue, cell type or biological body fluid. The comparison of protein patterns between healthy subjects and patients with a given pathological condition can be useful to identify specific diagnostics or prognostics biomarkers of diseases. Particularly, urinary proteomics has rapidly developed and has been extensively applied in the field of early diagnostics and differentiation of renal damage ([@ref1]).

Urine is a valuable source of proteins and peptides; it has the advantage of being obtained non-invasively, easily and frequently, and in a large quantity. It has been defined as a fluid biopsy of the kidney and urogenital tract, thus providing considerable information about these organs. Consequently, many changes in kidney and urogenital tract function may be detected in the urinary proteome ([@ref2]).

Urine proteomics studies were conducted in the search for early biomarkers of renal changes in:

1.  type 2 diabetic nephropathy (T2DN), a complication linked to diabetes, which leads to end-stage renal disease ([@ref3]);

2.  drug-induced nephrotoxicity in medication-overuse headache (MOH), a chronic disorder associated with overuse of analgesic drugs or compounds for acute headache ([@ref4]).

MATERIALS AND METHODS {#sec1-2}
=====================

Subjects {#sec2-1}
--------

### 1) Diabetic nephropathy {#sec3-1}

Diabetic patients were enrolled from the "Division of Nephrology, Dialysis and Renal Transplantation" of the University-Hospital of Modena and Reggio Emilia, Italy: 10 normoal-buminuric patients with type 2 diabetes (T2D), 12 T2DN patients with microalbuminuria (range 130-280 mg/mL) and/or proteinuria (\>10 mg/dL), and a control group of 12 healthy volunteer subjects with a history of regular renal function.

The duration of diabetes was similar in the two patients groups. Moreover, all groups were matched for age and gender ([@ref3]).

### 2) Drug-induced nephrotoxicity {#sec3-2}

A total of 87 MOH patients were recruited from the "Headache and Drug Abuse Center", University-Hospital of Modena and Reggio Emilia, Italy. They were divided into three groups, according to the type of the primary abused drug, as follows: 31 patients who consumed exclusively triptans, 27 non-steroidal anti-inflammatory drugs (NSAIDs) and 29 taking mixtures. Healthy volunteers (n=30) were enrolled as controls. Each group was matched for age and gender; moreover, patients showed similar MOH duration, days with headache/month and about daily drug intake. Kidney diseases and urogenital tract dysfunctions, together with other important illness, were considered as exclusion criteria ([@ref5]).

Both studies were in compliance with the ethical principles for medical research involving human subjects, in accordance with the Declaration of Helsinki. Written informed consent were received from both, patients and healthy subjects.

Urine proteomics analysis {#sec2-2}
-------------------------

Morning midstream urine samples were collected and immediately centrifuged at 800 g for 10 min at +4C°, to remove cell debris and contaminants. Commonly, human urine has a very diluted protein concentration and, at the same time, a high-salt content, which hampers the proteomicanalysis. Sample preparation is therefore a pivotal step in urinary proteomics, especially during two-dimensional polyacrylamide gel electrophoresis (2-DE) ([@ref2]). In order to concentrate proteins, eliminating the interfering salts, urine samples were treated with filter devices, 3 kDa MW-cut off (Merck Millipore). Subsequently, total protein content was estimated by the spectrophotometric Bradford method, and 100 mg of protein was premixed with a specific lysis buffer. The first-dimension separation (isoelec-trofocalization) was performed using IPG strips 17 cm long, wide pH range 3-10 (Bio-Rad), while in the second-dimension separation, 8-16% polyacrylamide gradient gels were used, that finally were staining with a silver-nitrate staining protocol. Afterwards, gels images were acquired with a calibrated densitometer (GS800 model, Bio-Rad) and analyzed by a specific image analysis software (PDQuest, Bio-Rad), to reveal differentially expressed protein spots among the patients and control groups ([@ref3], [@ref5]). The spots of interest were cut from the gels and subjected to trypsin digestion. Peptides were finally extracted and analyzed by the mass spectrometry using a quadrupole-time of flight-liquid chromatography mass spectrometer (Q-ToF-LC/MS, Agilent-Technologies).

In the second study (drug-induced nephrotoxicity), the results obtained by proteomic analysis were further confirmed and validated by Western blot and ELISA test ([@ref6]).

RESULTS AND DISCUSSION {#sec1-3}
======================

1) Diabetic nephropathy {#sec2-3}
-----------------------

Comparing the urinary proteomic profiles obtained by 2-DE analysis, 11 differential proteins were identified that progressively changed between controls and T2D and T2DN patients. Precisely, 8 proteins were significantly up-regulated: transthyretin precursor, Ig k chain C region, Ig k chain V-II region Cum, Ig k-chain V-III region SIE, carbonic anhydrase 1, retinol binding protein, beta-2-microglobulin precursor and beta-2-glycoprotein 1.

Except for the last one, all the other proteins were in the low MW range (\<30 kDa). Three proteins were found down-regulated: prostatic acid phosphatase precursor, ribonuclease 2 and kallikrein-3 ([Table 1](#table001){ref-type="table"}).

Proteomic analysis allowed to detect alterations of urinary proteins in both T2DN and T2D normoalbuminuric patients. Thus, this protein pattern might be of potential interest to identify diabetic patients prone to develop nephropathy, contributing to a better understanding of diabetic-related renal damage. The strength of proteomics in this research area has been confirmed also by recently published review articles ([@ref7], [@ref8]).

2) Drug-induced nephrotoxicity {#sec2-4}
------------------------------

In this study both qualitative and quantitative differences in urine of MOH patients were studied and revealed. Interestingly, by 2-DE combined with MS analysis, 21 over-excreted proteins and a significantly higher number of total protein spots were identified in the urine of NSAIDs, mixtures and triptans abusers compared to the controls ([Table 2](#table002){ref-type="table"}).

Some differentially expressed proteins detected by proteomic analysis were found to be strongly related to renal injury ([@ref9]), as assessed by an extensive literature review. Particularly, 4 proteins were validated by Western blot: prostaglandin-H2 D-synthase (PTGDS), uromodulin (UROM), alpha-1-microglobulin (AMBP) and cystatin-C (CYSC), as shown in [Figure 1](#fig001){ref-type="fig"}.

Immunoblotting allowed to confirm previous data of over-expression of these proteins in urine of MOH patients (especially NSAIDs and mixtures abusers) vs normal controls ([@ref6]).

Finally, PTGDS was further quantified by the ELISA test ([Figure 2](#fig002){ref-type="fig"}), which proved its significant increase in all MOH groups: mixtures (681 ± 218 ng/mL), NSAIDs (572 ± 135 ng/mL,) and triptans (450 ± 116 ng/mL), compared to the controls (303 ± 130 ng/mL). These data points, expressed as mean ± standard deviation, were in strict accordance with MS and Western blot results ([@ref6]).

The results of this study allowed to define the urinary protein profile of MOH, in relation to the type of drug abused. The use of powerful proteomic methodologies could permit to identify promising candidate biomarkers of kidney dysfunctions, and consequently those chronic headache patients at risk to develop drug-induced nephrotoxicity.

CONCLUSIONS {#sec1-4}
===========

In conclusion, urinary proteomics proved to be a suitable tool in nephro-toxicological research. Actually, its application may be useful in the search of early biomarkers, providing important diagnostics and prognostics indications.

Additionally, the study of the urinary proteome can offer significant data for a better understanding of renal pathophysiology.

![Western blot analysis](ejifcc-29-290-g001){#fig001}

![ELISA test of PTGDS protein](ejifcc-29-290-g002){#fig002}

###### 

Differentially expressed proteins detected in T2D and T2DN patients by MS

  Protein name                           Acc. number^[(a)](#fn001){ref-type="table-fn"}^   MW (kDa)   Function
  -------------------------------------- ------------------------------------------------- ---------- -------------------
  **Up-regulated proteins**                                                                           
  Transthyretin precursor                P02766                                            16.0       Hormone-binding
  Ig Kappa chain C-region                P01834                                            11.8       Immune response
  Ig Kappa chain V-ll region Cum         P01614                                            12.8       Antigen-binding
  Ig Kappa chain V-ll region SIE         P01620                                            11.9       Immune response
  Carbonic anhydrase 1                   P00915                                            28.8       Miscellaneous
  Plasma retinol-binding protein         P02753                                            23.3       Transport
  Beta-2-microglobulin precursor         P61769                                            13.8       Immune response
  Beta-2-glycoprotein 1                  P02749                                            39.6       Binding protein
  **Down-regulated proteins**                                                                         
  Prostatic acid phosphatase precursor   P15309                                            44.9       Dephosphorylation
  Ribonuclease 2                         P10153                                            18.9       Miscellaneous
  Kallikrein-3                           P07288                                            29.3       Hydrolysis

\(a\) Primary accession number from the SwissProt database.

###### 

Differentially expressed proteins identified by Q-ToF-LC/MS

  Protein name                               Acc. number^[(a)](#fn002){ref-type="table-fn"}^   MW (kDa)   Over-expression *vs* controls^[(b)](#fn003){ref-type="table-fn"}^       
  ------------------------------------------ ------------------------------------------------- ---------- ------------------------------------------------------------------- --- ----
  **Low-MW proteins**                                                                                                                                                             
  Prostaglandin-H2-D-isomerase               P41222                                            18.7       X                                                                   X   X
  Ig kappa chain C region                    P01834                                            11.8       X                                                                   X   NS
  Perlecan (fragment)                        P98160                                            479.2      X                                                                   X   X
  Transthyretin                              P02766                                            15.9       NS                                                                  X   NS
  Proactivator polypeptide                   P07602                                            9.11       X                                                                   X   X
  Nuclear transport factor 2                 P61970                                            14.6       X                                                                   X   X
  Fatty acid-binding protein                 Q01469                                            15.5       NS                                                                  X   X
  Beta-2-microglobulin                       P61769                                            11.7       NS                                                                  X   X
  Protein S100-A11                           P31949                                            11.8       NS                                                                  X   X
  Non-secretory ribonuclease                 P10153                                            18.9       X                                                                   X   NS
  Cystatin-C                                 P01034                                            13.3       X                                                                   X   NS
  Protein S100-A8                            P05109                                            10.8       X                                                                   X   X
  **Medium - MW proteins**                                                                                                                                                        
  Alpha-1-antitrypsin                        P01009                                            46.9       X                                                                   X   NS
  Actin, cytoplasmic!                        P60709                                            42.1       X                                                                   X   X
  Alpha-1-microglobulin                      P02760                                            39.9       X                                                                   X   NS
  Apolipoprotein H                           P02749                                            38.3       NS                                                                  X   NS
  Serpin B3                                  P29508                                            44.6       X                                                                   X   X
  Annexin Al                                 P04083                                            38.6       X                                                                   X   X
  **High - MW proteins**                                                                                                                                                          
  Serum albumin                              P02768                                            66.5       X                                                                   X   NS
  Uromodulin                                 P07911                                            69.7       X                                                                   X   X
  Inter-α-trypsin inhibitor heavy chain H4   Q14624                                            70.6       X                                                                   X   NS

\(a\) Primary accession number from the SwissProt database

\(b\) Expression difference calculated by the PDQuest software: x: significant, NS: not-significant
